Dear Editor, We would like to reply to "Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11years: Correspondence " regarding our article entitled "Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNTech) vaccine in children aged 5-11years: Results from an active pharmacovigilance study in central Italy. "
Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11 years: Author's reply to correspondence
Ripabelli, Giancarlo;Salzo, Angelo;Tamburro, Manuela
2023-01-01
Abstract
Dear Editor, We would like to reply to "Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11years: Correspondence " regarding our article entitled "Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNTech) vaccine in children aged 5-11years: Results from an active pharmacovigilance study in central Italy. "File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
